Non-Factor Therapies in Haemophilia: The Era of Factor VIII Mimetics and Targeted Rebalancing Agents
Lukas Graf · 2026
Read Non-Factor Therapies in Haemophilia: The Era of Factor VIII Mimetics and Targeted Rebalancing Agents by Lukas Graf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13331520.txt.
Description
Haemophilia care long meant replacing the missing clotting factor by vein, with peaks, troughs, and immune blockers as costs. Lukas Graf reviews the therapies that skip factor replacement altogether in 2026, an era of factor VIII mimics and rebalancing drugs.
Antibody mimics stand in for factor VIII's helper role and give steady protection from under-skin injections. Years of use of the lead mimic, emicizumab, show durable effect across patients with and without blockers. Newer mimics aim for more potency. Rebalancing agents instead mute the body's own anticoagulants, lifting clotting in both haemophilia A and B, though they demand care against overshoot. Graf also notes the special value of these drugs when the disease is acquired.
Catalog record
| CREATOR | Lukas Graf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |